Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15538346 | 1.00 | PDK2 (0.41) | PDK2CNR2ALOX5APFEN1GPR119 | |
| SCHEMBL15539072 | 0.98 | PDK2 (0.44) | PDK2CNR2ALOX5APFEN1GPR119 | |
| SCHEMBL15539075 | 0.98 | PDK2 (0.44) | PDK2CNR2ALOX5APFEN1GPR119 | |
| SCHEMBL15538810 | 0.90 | PDK2 (0.42) | PDK2CNR2SPHK1SPHK2ROCK2 | |
| SCHEMBL15538814 | 0.90 | PDK2 (0.42) | PDK2CNR2SPHK1SPHK2ROCK2 | |
| SCHEMBL15539764 | 0.90 | PDK2 (0.42) | PDK2CNR2SPHK1SPHK2ROCK2 | |
| SCHEMBL15538891 | 0.89 | CNR2 (0.42) | PDK2CNR2GPR119SPHK1SPHK2 | |
| SCHEMBL15538184 | 0.89 | CNR2 (0.42) | PDK2CNR2GPR119SPHK1SPHK2 | |
| SCHEMBL15539971 | 0.89 | CNR2 (0.42) | PDK2CNR2GPR119SPHK1SPHK2 | |
| SCHEMBL15537981 | 0.87 | PDK2 (0.44) | PDK2CNR2GPR119SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | claimed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | claimed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | PDK2 870/4885CNR2 42/4885ALOX5AP 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.